#AskDrDurie

Learn about the latest myeloma research. Get a front row seat at the most critical medical meetings. Watch Dr. Brian Durie, IMF Chairman, address issues that are important to the entire myeloma community. IMF TV brings it all to you.

Oct
17
What are bispecific antibodies?
In this week's video, Dr. Brian G.M. Durie explains how bispecific antibodies work and why they are being studied in clinical trials to treat myeloma. BOTTOM LINE:​ Bispecific antibodies are showing(...)
Oct
11
How does the FDA approval of next-generation sequencing (NGS) to test for MRD in multiple myeloma affect patients?
In this week’s video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma – next-generation sequencing (NGS) and next-generation flow (NGF). BOTTOM(...)
Sep
13
What is the latest on a new drug called selinexor?
In this week’s video, Dr. Brian G.M. Durie details the results of the STORM 2b trial, which uses selinexor in combination with dexamethasone to treat multiple myeloma patients who are refractory to(...)
Sep
06
If you have myeloma, should you undergo tests for DNA sequencing?
In this week’s video, Dr. Brian G.M. Durie comments on why it is not necessary for multiple myeloma patients to have their DNA sequenced.
Aug
30
If a myeloma patient has MRD-negative status, does that mean that patient is cured?
In this video, Dr. Brian G.M. Durie explains how researchers are studying minimal residual disease (MRD) testing further to better understand sustained MRD-negativity. BOTTOM LINE: ​ MRD-negative(...)
Aug
23
How is high-risk smoldering multiple myeloma diagnosed?
In this video, Dr. Brian G.M. Durie explains that high-risk smoldering myeloma (HRSMM) is diagnosed if a patient has CRAB features and myeloma-defining events. He also sheds light on a new set of(...)